Peer-influenced content. Sources you trust. No registration required. This is HCN.

Three-Drug Combination Induces Deep Remission in Treatment-Naive, R/R CLL

Are traditional cytotoxic chemotherapies becoming a thing of the past? This study in the Journal of Clinical Oncology shows a move toward targeted agents, as a combination of obinutuzumab, ibrutinib, and venetoclax induced deep remissions in patients with treatment-naive or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form